Equities Analysts Offer Predictions for RYTM FY2025 Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Analysts at HC Wainwright decreased their FY2025 earnings per share estimates for Rhythm Pharmaceuticals in a report issued on Monday, December 22nd. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($3.13) per share for the year, down from their previous forecast of ($3.09). HC Wainwright currently has a “Buy” rating and a $123.00 target price on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q4 2025 earnings at ($0.77) EPS.

A number of other equities analysts have also recently issued reports on the stock. Citigroup reaffirmed an “outperform” rating on shares of Rhythm Pharmaceuticals in a research note on Friday, December 12th. Guggenheim increased their price target on Rhythm Pharmaceuticals from $120.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Canaccord Genuity Group lifted their price objective on Rhythm Pharmaceuticals from $114.00 to $141.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Citizens Jmp upped their price objective on Rhythm Pharmaceuticals from $141.00 to $167.00 and gave the company a “market outperform” rating in a report on Friday, December 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Rhythm Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $126.47.

Rhythm Pharmaceuticals Trading Down 0.5%

Shares of NASDAQ RYTM opened at $112.35 on Wednesday. Rhythm Pharmaceuticals has a 1 year low of $45.90 and a 1 year high of $122.20. The firm’s 50-day moving average is $106.93 and its 200-day moving average is $94.84. The firm has a market capitalization of $7.50 billion, a PE ratio of -36.24 and a beta of 1.96.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.10). Rhythm Pharmaceuticals had a negative return on equity of 433.21% and a negative net margin of 110.32%.The firm had revenue of $51.30 million during the quarter, compared to analyst estimates of $50.71 million.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

Several large investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Rhythm Pharmaceuticals by 4.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,568 shares of the company’s stock worth $259,000 after acquiring an additional 110 shares during the period. Captrust Financial Advisors increased its holdings in Rhythm Pharmaceuticals by 0.7% during the 2nd quarter. Captrust Financial Advisors now owns 17,471 shares of the company’s stock worth $1,104,000 after purchasing an additional 114 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in shares of Rhythm Pharmaceuticals by 97.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock valued at $29,000 after purchasing an additional 141 shares during the period. Optiver Holding B.V. lifted its holdings in shares of Rhythm Pharmaceuticals by 65.2% in the third quarter. Optiver Holding B.V. now owns 365 shares of the company’s stock valued at $37,000 after purchasing an additional 144 shares in the last quarter. Finally, Teacher Retirement System of Texas lifted its holdings in shares of Rhythm Pharmaceuticals by 1.5% in the third quarter. Teacher Retirement System of Texas now owns 12,960 shares of the company’s stock valued at $1,309,000 after purchasing an additional 188 shares in the last quarter.

Insider Activity

In related news, insider Joseph Shulman sold 9,748 shares of the stock in a transaction that occurred on Thursday, October 30th. The stock was sold at an average price of $115.24, for a total transaction of $1,123,359.52. Following the completion of the sale, the insider directly owned 8,509 shares of the company’s stock, valued at approximately $980,577.16. This represents a 53.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Pamela J. Cramer sold 3,350 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $111.00, for a total transaction of $371,850.00. Following the sale, the insider owned 20,814 shares in the company, valued at $2,310,354. This trade represents a 13.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 30,350 shares of company stock valued at $3,436,340 over the last 90 days. Corporate insiders own 6.10% of the company’s stock.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.